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Introduction: We hypothesized that activating KRAS mu-
tations and inactivation of the liver kinase B1 (LKB1)
oncosuppressor can cooperate to sustain NSCLC aggres-
siveness. We also hypothesized that the growth advantage
of KRAS/LKB1 co-mutated tumors could be balanced by
higher sensitivity to metabolic stress conditions, such as
metformin treatment, thus revealing new strategies to
target this aggressive NSCLC subtype.
Methods: We retrospectively determined the frequency
and prognostic value of KRAS/LKB1 co-mutations in tissue
specimens from NSCLC patients enrolled in the TAILOR
trial. We generated stable LKB1 knockdown and LKB1-
overexpressing isogenic H1299 and A549 cell variants,
respectively, to test the in vitro efﬁcacy of metformin. We
also investigated the effect of metformin on cisplatin-
resistant CD133þ cells in NSCLC patient-derived xenografts.
Results: We found a trend towards worse overall survival in
patients with KRAS/LKB1 co-mutated tumors as compared to
KRAS-mutated ones (hazard ratio: 2.02, 95% conﬁdence in-
terval: 0.94–4.35, p ¼ 0.072). In preclinical experiments,
metformin produced pro-apoptotic effects and enhanced
cisplatin anticancer activity speciﬁcally in KRAS/LKB1 co-
mutated patient-derived xenografts. Moreover, metforminJournal of Thoracic Oncology Vol. 13 No. 11: 1692-1704prevented the development of acquired tumor resistance to
5 consecutive cycles of cisplatin treatment (75% response
rate with metformin-cisplatin as compared to 0% response
rate with cisplatin), while reducing CD133þ cells.
Conclusions: LKB1 mutations, especially when combined
with KRAS mutations, may deﬁne a speciﬁc and more
aggressive NSCLC subtype. Metformin synergizes with
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prevent or delay the onset of resistance to cisplatin by
targeting CD133þ cancer stem cells. This study lays the
foundations for combining metformin with standard
platinum-based chemotherapy in the treatment of KRAS/
LKB1 co-mutated NSCLC.
 2018 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Non–small cell lung cancer; Metformin; KRAS/
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Introduction
Lung cancer is the most frequent cause of cancer-
related death worldwide, accounting for more than
1.4 million deaths per year.1 NSCLC accounts for
approximately 85% of all lung cancers, and is poorly
sensitive to most of available treatment options, with
response rates ranging between 10% and 25% with
standard therapies.2 For the majority of patients
with advanced NSCLC, cytotoxic chemotherapy (ChT)
remains the cornerstone treatment. In recent years, in-
hibitors of constitutively active EGFR, ALK receptor
tyrosine kinase (ALK) or ROS1 kinases dramatically
improved tumor responses and clinical outcomes of pa-
tients with mutated tumors.3 Furthermore, pem-
brolizumab has recently replaced platinum-containing
ChT as the ﬁrst-line treatment for tumors expressing
programmed death ligand 1 in more than 50% of cancer
cells.4 When considered together, targeted therapies and
pembrolizumab represent approximately 30% of all ﬁrst-
line treatments, whereas platinum-based ChT remains
the preferred ﬁrst-line option for the remaining patients.
Another frequently altered gene in NSCLC is KRAS,
whose mutations are usually mutually exclusive with
EGFR, ALK and ROS1 mutations, and are found in
approximately 25% of all NSCLCs.5 Decades of intense
research to effectively inhibit constitutively active KRAS,
or to target its major downstream effectors, led to un-
satisfactory clinical results in NSCLC patients.6,7 So far, no
predictive or prognostic role for KRAS mutations have
been consistently documented.8-10 Some evidences sug-
gest that speciﬁc subgroups of KRAS-mutated tumors
with co-mutations in other crucial genes may display
speciﬁc clinical behavior, such an intrinsically aggressive
clinical course or exquisite response/resistance to ther-
apies.11-13 NSCLCs with activating KRAS mutations
frequently harbor other concurrent mutations in liver
kinase B1 (LKB1), long non-coding RNAs (p53), cyclin
dependent kinase 4/6 (CDK4/6) genes. In particular,
approximately 10% of all NSCLC are co-mutated for bothKRAS and LKB1.14,15 LKB1 is a tumor suppressor kinase
that is involved in regulating cell growth, metabolism, and
survival. Its major direct target is the protein kinase AMP-
activated catalytic subunit alpha 1 (AMPK), which is
activated in conditions of metabolic stress and orches-
trates an adaptive metabolic response that aims to spare
energy units and nutrients.16 For example, AMPK phos-
phorylates and inhibits acetyl-CoA carboxylase alpha
(ACC1) and 3-hydroxy-3-methylglutaryl-CoA reductase
(HMGCR) enzymes, which are involved in fatty acid and
cholesterol biosynthesis, two energy-consuming pro-
cesses. Moreover, by phosphorylating TSC complex sub-
unit 2 (TSC2), AMPK inhibits the mammalian target of
rapamycin (mTOR) kinase, with the consequent inhibi-
tion of protein synthesis (Supplementary Fig. 1).17 Recent
studies have revealed that KRAS/LKB1 co-mutated
pancreatic cancer cells display a “hypermetabolic state”
characterized by enhanced glycolysis and serine-glycine-
one carbon metabolism.18 Another preclinical study
published by Shackelford et al.11 has shown that the
biguanide phenformin produces meaningful in vitro and
in vivo antitumor effects in KRAS/LKB1 co-mutated
NSCLC. In particular, the authors of this paper sug-
gested that LKB1 inactivation makes NSCLC cells unable
to halt energy and anabolite-consuming processes even in
conditions of metabolic stress caused by phenformin,
while constitutively active KRAS forces cells to duplicate
their DNA and other intracellular structures, thus accel-
erating energy depletion, damage to intracellular com-
ponents, and induction of cell apoptosis.
In this study, we hypothesized that the metabolic
frailty of KRAS/LKB1 co-mutated NSCLC cells could be
exploited pharmacologically by combining drugs that
affect cell metabolism with compounds that increase
intracellular stress by interfering with DNA replication
and repair, such as platinum compounds. To induce
metabolic stress, we used the antidiabetic drug metfor-
min, which has revealed interesting antitumor activity in
both in vitro and in vivo preclinical studies. Metformin
has been reported to be active against ChT-resistant
cancer stem cells (CSCs) in different cancer types.19,20
Moreover, metformin use in diabetic patients has been
associated with reduced risk of several cancers, as well
as a better prognosis in patients with advanced malig-
nancies, including NSCLC. The proposed direct anti-
cancer mechanism of metformin likely relies on the
inhibition of complex I of the electron transport chain,
with the consequent reduction of intracellular adenosine
triphosphate levels and the induction of an energetic
crisis in tumor cells.21,22 However, the antitumor in vitro
effects of metformin vary across different cancer types.23
By taking advantage of the outcome data obtained in
the TAILOR trial, we retrospectively assessed frequency
and prognostic value of KRAS/LKB1 co-mutation in
Table 1. Patient Characteristics
KRAS
mut/LKB1
wt n ¼ 34
KRAS
mut/LKB1
mut n ¼ 13
Overall
N ¼ 47
Age (y)
Mean (SD) 63.5 (7.6) 64.1 (8.6) 63.6 (7.8)
Median
(Q1 - Q3)
63.9 (59.0-
68.5)
66.9 (58.2-
70.7)
64.0 (58.2-
70.1)
Min - Max 48.0 - 78.5 50.2 - 76.4 48.0 - 78.5
Sex
Male 24 (70.6) 9 (69.2) 33 (70.2)
Female 10 (29.4) 4 (30.8) 14 (29.8)
Performance
status
0/1 32 (94.1) 13 (100) 45 (95.7)
2 2 (5.9) 0 (0.0) 2 (4.3)
Smoking history
Never smoker 4 (11.8) 2 (15.4) 6 (12.8)
Former smoker 18 (52.9) 6 (46.2) 24 (51.1)
Current smoker 12 (35.3) 5 (38.5) 17 (36.2)
Stage at diagnosis
I - IIIA 14 (41.2) 3 (23.1) 17 (36.2)
IIIB/IV 20 (58.8) 10 (76.9) 30 (63.8)
Stage at randomization
IIIA-IIIB 5 (14.7) 1 (7.7) 6 (12.8)
IV 29 (85.3) 12 (92.3) 41 (87.2)
Grade
G1 0 (0.0) 3 (33.3) 3 (8.8)
G2 9 (36.0) 2 (22.2) 11 (32.4)
G3 16 (64.0) 4 (44.4) 20 (58.8)
Missing 9 4 13
Histology
Adenocarcinoma 29 (85.3) 12 (92.3) 41 (87.2)
Squamous þ
NOS
3 (8.8) 1 (7.7) 4 (8.5)
Other 2 (5.9) 0 (0.0) 2 (4.3)
First-line treatment
pem/cis 11 (32.4) 6 (46.2) 17 (36.2)
gem/cis 6 (17.6) 4 (30.8) 10 (21.3)
nav/cis 6 (17.6) 1 (7.7) 7 (14.9)
gem/carbo 3 (8.8) 1 (7.7) 4 (8.5)
pem/carbo 3 (8.8) 0 (0.0) 3 (6.4)
nav/carbo 2 (5.9) 0 (0.0) 2 (4.3)
cis/gem/bev 1 (2.9) 0 (0.0) 1 (2.1)
nav 1 (2.9) 0 (0.0) 1 (2.1)
Other 1 (2.9) 0 (0.0) 1 (2.1)
Unknown 0 (0.0) 1 (7.7) 1 (2.1)
Randomization arm
docetaxel 16 (47.1) 10 (76.9) 26 (55.3)
erlotinib 18 (52.9) 3 (23.1) 21 (44.7)
Values are presented as n (%) unless otherwise indicated.
G1, well differentiated; G2, moderately differentiated; G3, poorly differ-
entiated; NOS, not other speciﬁed; pem, pemetrexed; gem, gemcitabine;
nav, navelbine; cis, cisplatin; carbo, carboplatin; bev, bevacizumab; SD,
standard deviation; Q1, ﬁrst quartile; Q3, third quartile; Min, minimum;
Max, maximum; wt, wild type; mut, mutation.
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metformin to induce energetic crisis in NSCLC cell lines
with different KRAS/LKB1 mutational status. We gener-
ated stable LKB1 knockdown and LKB1 overexpressing
isogenic H1299 and A549 cells variants, respectively,
and tested the hypothesis that KRAS/LKB1 co-mutated
tumors are not able to counteract metformin-induced
energy crisis, thus undergoing enhanced apoptosis af-
ter in vitro treatment. Finally, we exploited NSCLC
patient-derived xenografts (PDXs), which closely mimic
patients tumors, to investigate therapeutic activity of
metformin plus cisplatin combination in the context of
LKB1/KRAS co-mutated tumors.24
Materials and Methods
Clinical Data
TAILOR (ClinicalTrials.gov, trial number
NCT00637910) was a nonproﬁt multicenter, open label,
randomized trial, funded by the Italian Regulatory
Agency AIFA and conducted by 52 Italian hospitals. The
clinical results of the TAILOR trial have been pub-
lished.10 Patients with EGFR wild-type (WT) and known
KRAS mutational status progressing after platinum-
based chemotherapy were randomized in a phase 3
trial to receive either docetaxel or erlotinib as their
second-line therapy. The primary endpoint of the trial
was overall survival (OS) after second-line treatment.
Secondary endpoints included progression-free survival
(PFS) and objective response rate. A pre-speciﬁed anal-
ysis was conducted also for the ﬁrst-line outcomes.25
The protocol was approved by the human investiga-
tional review board at each participating site, and
voluntary written informed consent was obtained
from each patient. All experiments were performed in
accordance with the Declaration of Helsinki. The
remaining fractions of tissue samples collected at patient
enrollment in the TAILOR study were used for the pre-
sent one.
Statistical Analysis
Only KRAS-mutated tumors were considered for the
present analysis. The chi-squared test was used to
analyze the associations between LKB1 status and
different clinical variables. PFS was deﬁned as the time
from the randomization up to the date of progression or
death from any cause, whichever came ﬁrst. OS was
deﬁned as the time from randomization up to the date of
death from any cause. Subjects who had not progressed
or died while on study were censored at the last disease
assessment date. Survival curves were estimated with
the Kaplan-Meier method, and statistical signiﬁcance
between survival curves was assessed through the log-
rank test. Cox proportional hazards models were usedto assess at univariate and multivariable (adjusted for
Eastern Cooperative Oncology Group performance status
[ECOG-PS], sex, histotype, smoking history, and treat-
ment arm) analysis the association of speciﬁc mutational
Figure 1. Kaplan Meier curves for progression-free survival (A) and overall survival (B) in KRASMUT/LKB1WT versus KRASMUT/
LKB1MUT patients enrolled within the TAILOR trial. Hazard ratio: univariate (unadjusted) and multivariate (adjusted for ECOG-
PS, sex, histotype, smoking history and treatment arm). WT, wild-type; LKB1, liver kinase B1; HR, hazard ratio; Chi2, chi
squared; CI, conﬁdence interval; ECOG-PS, Eastern Cooperative Oncology Group performance status.
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as hazard ratios (HRs) and their corresponding 95%
conﬁdence intervals (95%CIs). All statistical tests weretwo-sided and a p < 0.05 was considered statistically
signiﬁcant. Statistical analyses were performed using
SAS version 9.4 (SAS Institute, Cary, North Carolina).
Table 2. Cox Models — Multivariate Analysis for PFS and OS
PFS OS
HR 95% CI p Value HR 95% CI p Value
LKB1 (mut vs. WT)a 1.81 0.86–3.82 0.118 2.03 0.94–4.40 0.072
Sex (female vs. male) 1.17 0.56–2.48 0.674 0.61 0.28–1.31 0.206
Smoking habits (Current smokers vs. never/former) 1.93 0.94–3.94 0.072 2.82 1.32–6.06 0.008
Performance status (2 vs. 0/1) 4.71 0.62–35.57 0.133 4.54 0.45–45.69 0.199
Histology (reference adenocarcinoma)
Squamous 0.64 0.15–2.76 0.547 0.45 0.07–3.01 0.413
Other 3.03 0.60–15.26 0.179 0.87 0.18–4.21 0.857
Randomization arm (docetaxel vs. eroltinib) 0.73 0.36–1.47 0.377 0.89 0.43–1.84 0.754
Stage at random (IV vs. IIIA/IIIB) 0.85 0.31–2.32 0.751 0.94 0.37–2.42 0.899
aAdjusted on the initial stage.
PFS, progression-free survival; HR, hazard ratio; CI, conﬁdence interval; OS, overall survival; mut, mutation; WT, wild-type.
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The human NSCLC cell lines A549 (KRASG12S/
LKB1del) and H1299 (KRASWT/LKB1WT) were obtained
from the American Type Culture Collection. Cells were
cultured in Roswell Park Memorial Institute (RPMI)–
1640 medium (Lonza, Basel, Switzerland), supplemented
with 10% (volume/volume) fetal bovine serum (Lonza)
and a solution of 100 U/mL penicillin and 100 U/mL
streptomycin (Lonza). For cellular assays see
Supplementary Material and Methods
Patient-Derived Xenograft Treatments
Patient-derived xenografts (PDXs) were established
as previously described.26 The experimental protocol
was approved by the C.E.S.A. (Ethical Committee for
Animal Experimentation, of the National Cancer Institute
Foundation), and animal experimentation was per-
formed following guidelines drawn-up by C.E.S.A.
according to the guidelines for the welfare and use of
animals in cancer research.27 PDXs were implanted,
starting from a previously established NSCLC PDXs
platform in 5-week-old severe combined immune deﬁ-
ciency (SCID) mice.24 Groups of four mice, bearing a PDX
sample in each ﬂank for a total of n ¼ 8 tumors per
group were treated once a week for 3 weeks with
intraperitoneal injection of 5 mg/kg cisplatin (Teva,
Petah Tikva, Israel) and/or daily with 100 mg/kg or 800
mg/kg metformin (per gavage, 2 doses of 50 mg/kg or
400 mg/kg every 10 to 14 hours). Tumor growth was
followed by caliper once a week and results were
analyzed using GraphPad Prism software (La Jolla,
California). Response rate was calculated as previously
decribed.24 Mice were weighed twice a week and no
weight loss was observed (Supplementary Fig. 2). Serial
transplantation experiment was performed as previ-
ously reported.28Results
LKB1 Mutations as Prognostic Factors
To investigate if KRAS/LKB1 co-mutated tumors
represent a distinct subgroup of NSCLC endowed with
higher clinical aggressiveness, we retrospectively
analyzed data from 222 patients enrolled in the TAILOR
trial between October 2007 and March 2012. Of these,
134 tumor tissue specimens were available for further
molecular analyses (Supplementary Fig. 3). The main
characteristics of our cohort of patients are summarized
in Table 1. In particular, 47 patients (35.1%) had KRAS-
mutated tumors, whereas LKB1 mutations were found in
21 (15.7%) patients (Supplementary Tables 1 and 2).
Thirteen patients (9.7% of all patients and 27.7% of
KRAS-mutated patients) harbored mutations in both
KRAS and LKB1 genes. Among different variables
explored, we only found a positive association between
double KRAS/LKB1 co-mutations and low-grade tumors
(p ¼ 0.004) (Table 1). At a median follow-up of 63
months, 46 patients had progressed (44 died and 2
experienced disease progression without death). Among
patients with KRAS-mutated tumors, median PFS for
LKB1-mutated and LKB1-WT patients was 2.7 and 3.4
months, respectively (Fig. 1A). LKB1 status was nonsig-
niﬁcantly associated with PFS at both univariable anal-
ysis (HR: 1.62, 95% CI: 0.82–3.19, p ¼ 0.163) and
multivariate analysis, which adjusted for ECOG-PS, sex,
histotype, smoking history, and treatment arm (HR: 1.77,
95% CI: 0.85–3.68, p ¼ 0.125) (Table 2). Differences in
median OS were more discernible: 4.4 and 10.5 months
for KRAS/LKB1 co-mutated and KRAS-mutated LKB1-WT
patients, respectively (Fig. 1B). As in the case of PFS, the
association between LKB1 status and patient OS was
non-statistically signiﬁcant at both univariable and
multivariable analysis (HR: 1.78, 95% CI: 0.90–3.52,
p ¼ 0.095; HR: 2.02, 95% CI: 0.94–4.35, p ¼ 0.072 for
Figure 2. Effects of metformin on A549 (KRASG12S/LKB1del) and H1299 (KRASWT/LKB1WT) NSCLC cell line. (A) Dose-effect
curve shows that both cell lines are affected by biguanide treatment in a similar way in terms of number of live cells af-
ter 24 hours of treatment. (B) Annexin V staining shows that 50 mmol/L metformin treatment for 24 hours induces a 10-fold
increase and 7.6-fold increase of apoptosis induction in A549 and H1299 cells, respectively. These differences are exacer-
bated with 250 mmol/L metformin treatment for 24 hours where the biguanide induces a 46.2-fold increase and 18.5-fold
increase in A549 and H1299 cells, respectively. *p < 0.05; **p < 0.01 compared to controls; #p < 0.05; ##p < 0.01
compared to 50 mM metformin. (C) Metformin increases apoptosis induced by cisplatin in A549 transfected with control
plasmid (pBABE) but not in A549 cells with ectopic expression of wild-type LKB1 (LKB1WT) *p < 0.05; **p < 0.01; compared to
untreated control. §§§p < 0.001 LKB1WTcompared to pBABE cells. ###p < 0.001 cisplatin-treated compared to cisplatin and
metformin treated. (D) Metformin increases apoptosis induced by cisplatin treatment only in isogenic H1299 KRASG12C/
LKB1del cell line. *p < 0.05; compared to control cells #p < 0.01; cisplatin-treated compared to cisplatin-and-metformin
treated cells. pBABE, control plasmid; LKB1, liver kinase B1.
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(Table 2). Kaplan Meier curves for PFS and OS are
depicted in Figures 1A and B, respectively.
Effects of Metformin Treatment in NSCLC
Cell Lines
Having established that LKB1/KRAS co-mutation has
no signiﬁcant prognostic value in advanced NSCLC pa-
tients, we investigated the ability of metformin to
selectively target LKB1/KRAS co-mutated NSCLC cells
in vitro. To this aim, we treated A549 (a model of LKB1/
KRAS co-mutated NSCLC) and H1299 (a model of
LKB1WT/KRASWT NSCLC) cells with increasingmetformin concentrations and assessed cell growth rate.
Metformin inhibited growth to a similar extent in both
cell lines, irrespective of the mutational status of KRAS
and LKB1. At high metformin concentration (250 mmol/
L), growth was almost completely inhibited, and the
lowest concentration that showed a partially inhibitory
effect was 50 mmol/L (Fig. 2A). Metformin also reduced
mitochondrial membrane potential in both cell lines
(Supplementary Fig. 4A). We then investigated if met-
formin induced differential pro-apoptotic effects
depending on KRAS and LKB1 mutational status. To
do so, we determined the percentage of annexin V pos-
itivity in untreated and in metformin-treated cells.
1698 Moro et al Journal of Thoracic Oncology Vol. 13 No. 11
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apoptosis rates in A549 cells (10-fold increase in
metformin-treated cells compared to control cells) than
in H1299 cells (7.6-fold increase) (Fig. 2B), whereas cell
cycle arrest in the G1 phase was only induced in H1299
cells (Supplementary Fig. 4B). This difference in the
apoptotic rate among the two cell lines was further
exacerbated with a metformin concentration of 250
mmol/L (46.2-fold increase and 18.5-fold increase in
A549 and H1299, respectively) (Fig. 2B). To investigate
if this differential sensitivity to metformin-induced
apoptosis actually depends on the mutation status of
KRAS and LKB1 genes, we generated A549 LKB1WT cells
and H1299 cells with different KRAS and LKB1 status
(KRASWT/LKB1WT, KRASG12C/LKB1WT, KRASWT/LKB1del,
or KRASG12C/LKB1del). However, because metformin
concentrations used in previous experiments are highly
super-physiological and cannot be reached in vivo
without causing potentially lethal toxicities, we explored
lower metformin concentrations in combination with
cisplatin, the reference compound for the ﬁrst-line
treatment of advanced NSCLC. In parental A549 cells,
relatively low metformin concentration (5 mmol/L)
signiﬁcantly enhanced cisplatin-induced apoptosis (9-
fold and 17-fold annexin V positivity increase
compared to controls in cisplatin-treated and cisplatin
plus metformin-treated cells, respectively), whereas this
effect was absent in A549 LKB1WT cells (Fig. 2C). Similar
results were obtained with H1299 isogenic cell lines,
where 5 mmol/L metformin enhanced cisplatin-induced
apoptosis speciﬁcally in double mutated H1299-
KRASG12C/LKB1del cells (1.2-fold and 12.1-fold annexin V
positivity increase compared to controls in cisplatin
treated and cisplatin and metformin treated cells,
respectively). Noticeably, A549 LKB1WT cells showed a
fold change in annexin V positive cells similar to that
observed in H1299 WT/WT cells (2- and 1.2-fold increase,
respectively) and A549 cells showed a fold changeFigure 3. In vivo treatments of PDX111 (KRASG12V/LKB1WT) and
decrease in tumor growth at 100 mg/kg daily dosage in PDX1
dosage in PDX73. (B) Immunohistochemistry analysis cleaved cas
3 expression in PDX111 remains stable upon metformin treatm
rant) and at 800 mg/kg (750 positive cell/quadrant). On the co
metformin doses (920, 615, 550 positive cells/quadrant in untr
respectively). In the KRAS/LKB1 co-mutated PDX73, metform
increase in cleaved caspase 3 with increasing metformin dosage
kg and 800 mg/kg metformin-treated tumors, respectively); w
those of untreated tumors (950, 950, 1000 positive cells/qua
treated tumors, respectively). Hematoxylin-eosin staining sho
double-mutated PDX73 upon metformin treatment. (C) Increas
effect of biguanide treatment on PDX growth is appreciable onl
(800 mg/kg) ameliorates cisplatin effects only in KRAS/LKB1 co
alone, cisplatin alone, or a combination of the two are appre
and serial treatment cycles of cisplatin or cisplatin and m
Cisplatin-treated tumors progressively become resistant to trea
metformin last for 5 cycles with a progressive increase in the rcomparable to that of H1299G12C/del cells (17- and
12.1-fold increase, respectively) (Fig. 2D) when treated
with the combination of cisplatin and metformin. More-
over, metformin was able to counteract cisplatin-induced
increase of CD133þ CSCs in both A549 and H1299 cell
lines (48% and 44% average prevention of cisplatin-
induced enrichment, respectively (Supplementary
Fig. 4C).
Altogether, these data indicate a role for functional
LKB1 in preventing metformin-induced apoptosis and
enhancement of cisplatin cytotoxic effects, especially in a
KRAS-mutated background.Role of LKB1 in the In Vivo Response to Cisplatin
and Metformin Cotreatment in NSCLC PDXs
To assess the in vivo effects of LKB1 inactivation on
metformin-induced apoptosis in KRAS-mutated NSCLC, we
treated the following two PDXs models: PDX111
(KRASG12V/LKB1WT) and PDX73 (KRASG12V/ LKB1K287X).
Low metformin dosages (100 mg/kg daily) partially
inhibited tumor growth in LKB1WT PDX111 (50.5 ± 14.8%
maximal growth inhibition [MGI]), but not in LKB1-
mutated PDX73 (MGI of 21.8 ± 19.9%) (Fig. 3A). No
apoptosis induction was appreciable in PDX111 tumors,
whereasmetformin increased the levels of cleaved caspase
3 in the LKB1/KRAS co-mutated PDX73 model (Fig. 3B)
despite the lack of meaningful tumor shrinkage. Moreover,
loss of LKB1 in PDX73 was associated with increased tu-
mor necrosis following metformin treatment, suggesting
an impaired capacity of LKB1-deﬁcient tumor to adapt to
themetabolic stress caused by biguanide therapy (Fig. 3B).
When we increased metformin dosage to 800 mg/kg
daily, tumor growth was inhibited comparably to the
100 mg/kg dosage in PDX111 (49.0 ± 25.5% MGI),
whereas dose-dependent decrease in tumor volume was
appreciable in PDX73 (41.1 ± 11.7% MGI) (Fig. 3C).
Increasing metformin dosages was associated withPDX73 (KRASG12V/LKB1K287X). (A) Metformin induces a slight
11, and has no effects on tumor growth at 100 mg/kg daily
pase 3 and Ki-67 expression of treated PDXs. Cleaved caspase
ents both at 100 mg/kg (average of 600 positive cells/quad-
ntrary, Ki-67 expression gradually decreases with increasing
eated, 100 mg/kg and 800 mg/kg metformin-treated tumors,
in induces an increase of apoptosis, as shown by a gradual
(80, 150, 750 positive cells/quadrant in untreated, 100 mg/
hereas Ki-67 expression remains at levels comparable with
drant in untreated, 100 mg/kg and 800 mg/kg metformin-
ws necrotic areas (highlighted with an asterisk [*]) only in
ing metformin dosage to 800 mg/kg daily, a dose-dependent
y in KRAS/LKB1 co-mutated PDX73. (D) Metformin treatment
-mutated PDX73, whereas no differences between metformin
ciable in LKB1 wild-type PDX111. (E) Serial transplantation
etformin combination in KRAS/LKB1 co-mutated PDX73.
tments, whereas effects of the combination of cisplatin and
esponse rate (F). LKB1, liver kinase B1.
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expression in PDX111, and a dramatic increase in
cleaved caspase 3 positivity in PDX73 model (Fig. 3B).
Moreover, a more intense expression of pAMPK in
PDX111 compared with PDX73 tumors after 800 mg/kg
metformin treatment was appreciable (Supplementary
Fig. 5), suggesting the involvement of AMPK in the
response of tumors to the biguanide. Finally, metformin
synergized with cisplatin to reduce tumor size specif-
ically in the PDX73 model (Fig. 3D and Supplementary
Table 3), thus recapitulating results obtained with
in vitro experiments.
Altogether, these data suggest that metformin
differentially affects NSCLC cell growth and survival in a
way that depends on LKB1 and KRAS mutational status:
in particular, high-dose metformin halts tumor growth
by inhibiting cancer cell proliferation in KRAS-mutated
LKB1-WT NSCLC, while it promotes apoptosis of LKB1/
KRAS co-mutated NSCLC cells. Moreover, LKB1/KRAS
co-mutated tumors are speciﬁcally sensitive to the
cisplatin-metformin combination.Serial Transplantation Experiments
Primary or acquired resistance to cytotoxic ChT is a
common and apparently insurmountable problem for
patients with advanced NSCLC. To investigate if met-
formin affects tumor sensitivity throughout subsequent
cycles of cisplatin treatment, we performed a serial
transplantation experiment. After ﬁve serial trans-
plantations and 5 cycles of cisplatin treatment, PDX73
(LKB1mut/KRASmut) became almost completely resistant
to ChT. On the contrary, 5 cycles of metformin and
cisplatin combination produced long-lasting effects in
terms of tumor volume shrinkage (Fig. 3E and
Supplementary Table 4). The response rate of tumors
treated with cisplatin progressively decreased after each
serial transplantation cycle (50% of cases underwent
progression of disease (PD) and 50% partial response at
ﬁrst cycle, whereas 100% of tumors showed PD at the
ﬁfth cycle). Conversely, the metformin-cisplatin combi-
nation progressively increased tumor response rate
across subsequent treatment cycles (50% PD and 50%
partial response at ﬁrst cycle versus 12.5% PD and
37.5% PR; 12.5% complete response and 37.5% main-
tained complete response at ﬁfth cycle) (Fig. 3F).Figure 4. Fluorescence-activated cell sorting (FACS) analysis o
treated with cisplatin or cisplatin and metformin during the seria
increases at each passage in the cisplatin-treated tumors and th
formin– treated tumors. In the last serial passage, when tumors b
no more appreciable in terms of CSCs enrichment, whereas in th
percentage is appreciable. (C) Tumors lag time (time tumors need
cisplatin-and-metformin–treated tumors compared to both co
counteracting cisplatin-induced CSCs enrichment is appreciableThese data suggest that metformin is able not only to
acutely boost the anticancer effects of cisplatin, but also
to progressively reduce the occurrence of chemo-
resistance in a KRAS/LKB1 co-mutated preclinical model.CSC Involvement in the In Vivo Response to
Metformin
Based on our in vitro ﬁndings in A549 and H1299
cells, we hypothesized that metformin synergizes with
cisplatin to kill the population of chemoresistant CSCs,
which can repopulate the tumor by progressively
increasing the number of chemoresistant cells. To test
this hypothesis, we analyzed the content of CD133þ cells
in PDX73 LKB1/KRAS co-mutated tumors during serial
transplantation experiments. Fluorescence-activated cell
sorting analysis of tumors after the ﬁrst cycle of treat-
ment showed enrichment of CD133þ cells in cisplatin-
treated as compared to vehicle-treated tumors. This
enrichment was partially reverted by metformin-
cisplatin (MC) combination (0.94%, 1.95%, and 1.25%
CD133þ cells in vehicle-, cisplatin-, and MC-treated tu-
mors, respectively). CSC enrichment in cisplatin-treated
tumors, as well as CSC decrease in MC-treated ones,
was also observed after the second treatment cycle
(0.84%, 2.22%, and 0.47% CD133þ cells in vehicle-,
cisplatin-, and MC-treated tumors, respectively). After
four treatment cycles, that is, when tumors treated with
cisplatin alone had become almost completely cisplatin-
resistant, we no longer detected any CD133þ enrichment
in cisplatin-treated tumors, whereas a decrease in
CD133þ CSCs was still appreciable in MC-treated ones
(0.91%, 0.78%, and 0.38% CD133þ cells in vehicle-,
cisplatin-, and MC-treated tumors, respectively) (Figs. 4A
and B). Moreover, the time needed by tumors to reach
the target volume of 150 mm3 (lag time) progressively
increased in tumors treated with the MC combination
compared to the lag time of vehicle- or cisplatin-treated
tumors (Fig. 4C). A similar effect of metformin in
reducing CSCs was also appreciable in LKB1WT PDX111,
although it was less pronounced (33.7% decrease of the
2,2-fold cisplatin-induced CSCs enrichment and 69.3%
decrease of the 2.1-fold CSCs enrichment observed in
PDX111 and PDX73, respectively) (Fig. 4D).
Altogether, these data suggest that the MC combina-
tion can speciﬁcally target CD133þ cells in KRAS/LKB1f tumor samples from KRAS/LKB1 co-mutated PDX73 tumors
l transplantation experiment. (A, B) CD133þ CSCs percentage
is CSCs enrichment is counteracted in the cisplatin-and-met-
ecame completely resistant to treatment, cisplatin effects are
e cisplatin-and-metformin–treated tumors a decrease of CSCs
to reach 150mm3 volume after implant) gradually increases in
ntrols and cisplatin-treated tumors. (D) A similar effect on
also in KRASG12V/LKB1WT PDX111. LKB1, liver kinase B1.
1702 Moro et al Journal of Thoracic Oncology Vol. 13 No. 11co-mutated NSCLC PDXs, thus preventing or delaying
resistance to cisplatin.
Discussion
KRAS oncogenic mutations are found in approximately
20% to 25% of NSCLCs, and are implicated in the stim-
ulation of cancer cell growth, proliferation, and metabolic
reprogramming.5,29 However, despite decades of intense
research, no truly active therapies to target constitutively
active KRAS have been found yet.6,7 The prognostic
role of KRAS mutations remains debatable, and the
different genetic variants described so far are not clearly
associated with speciﬁc clinical behaviors.8-10,30,31
Our working hypothesis is that genetic alterations
co-occurring with KRAS activating mutations may deﬁne
NSCLC subgroups characterized by different prognosis
and/or response to speciﬁc treatments, possibly opening
up new possibilities of therapies targeted to speciﬁc
populations of KRAS-mutated NSCLC patients. For
instance, mutations in LKB1, p53, and CDK4/6 co-occur
with KRAS mutations in a clinically meaningful percent-
age of NSCLCs, and a negative prognostic role of KRAS/
LKB1 co-mutations in NSCLC has been recently re-
ported.13-15 Consistently with these ﬁndings, we found
that NSCLC patients with tumors bearing KRAS/LKB1 co-
mutations, and receiving second-line treatment within
the TAILOR trial, had a trend towards poorer PFS and OS
when compared to patients with KRAS-only mutated tu-
mors.10 Based on our results, LKB1mutations may deﬁne
a more aggressive subset of KRAS-mutated NSCLC, as
previously reported.32,33 Higher aggressiveness of LKB1-
mutated tumors could result from the loss of LKB1
oncosuppressive function, which is involved in regulating
cancer cell growth and proliferation on the basis of
nutrient availability.17 LKB1 loss, as caused by inactivat-
ing mutations or deletions of the LKB1 gene, could make
cancer cells unresponsive to nutrient starvation and en-
ergetic stress, thus accelerating their growth even when
nutrients (e.g., glucose, amino acid) are scarce. When
combinedwith activating mutations in oncogenes, such as
KRAS, which stimulates unrestrained cell growth, prolif-
eration and energy-requiring anabolic processes, LKB1
inactivation may confer a particularly aggressive clinical
phenotype associated with reduced patient survival.
In our preclinical experiments, we tested the hy-
pothesis that LKB1 mutations, which are associated with
aggressive growth phenotype in the absence of an
effective anticancer treatment, may confer metabolic
frailty to tumors with KRAS-induced deregulation of cell
growth and proliferation. We showed that supra-
physiological dosages of metformin, which causes
energetic stress in cancer cells by interfering with
mitochondrial activity, selectively induce apoptosis in
KRAS/LKB1 co-mutated models (A549 cells and PDX73),but not in KRASWT/LKB1WT cells (H1299) or in the
KRASMUT/LKB1WT PDX (PDX111), where the activation of
the LKB1/AMPK signaling pathway reduces cell prolif-
eration, thus reducing metabolic requirements and pre-
venting metabolic crisis in cancer cells.21 This result was
not surprising because recently published data have
shown a meaningful pro-apoptotic effect of the bigua-
nide phenformin, a more potent analog of metformin,
speciﬁcally in KRAS/LKB1 co-mutated NSCLC cells.11
However, both in Shackelford et al.11 and in our study,
the biguanide dosages used are by far too high to be
reached in the plasma of cancer patients.
In the perspective of future clinical applications, our
main ﬁnding is that metformin is capable of enhancing
cisplatin-induced in vitro pro-apoptotic and in vivo
antitumor effects speciﬁcally in KRAS/LKB1 co-mutated
tumors. Moreover, metformin prevented secondary
resistance to cisplatin and actually progressively
enhanced cisplatin-induced antitumor effects speciﬁcally
against KRASG12V/LKB1K287X NSCLC in vivo models.
The possibility that the safe and low-cost drug met-
formin prevents or substantially delays the onset of
secondary resistance to platinum-based ChT is highly
relevant from a clinical point of view and is worth being
explored in the clinical setting. In the clinical setting,
cisplatin-based combinations (with pemetrexed or
gemcitabine) are the standard ﬁrst-line options to treat
NSCLCs lacking speciﬁc oncogenic addiction or strong
programmed death ligand 1 expression. Although in this
study we did not explore the effects of metformin in
combination with platinum-based doublet chemo-
therapy, our ﬁndings are signiﬁcant because cisplatin
represents the compounds with the most relevant anti-
cancer activity, and is actually the backbone of these
combinations. Based on our ﬁndings, metformin could
prevent cisplatin-induced increase of CD133þ cells,
which we previously reported to represent a highly
tumorigenic, cisplatin-resistant cell subpopulation
enriched of cancer initiating cells with high dissemi-
nating potential.28,34 These ﬁndings suggest a potential
mechanism by which metformin could prevent acquired
resistance to cisplatin in KRAS/LKB1 co-mutated NSCLC.
A limitation of these in vivo experiments consists in
the high metformin dosages used. Indeed, 800 mg/kg
metformin/d approximately correspond to a daily
dosage of 3891 mg for a 60-kg patient, whereas the
maximum safe dose of metformin is 2550 mg/d in dia-
betic patients, and could be lower in combination with
cisplatin in NSCLC patients.35 Thus, to envisage a clinical
application of metformin for cancer treatment, further
studies will be needed to assess either efﬁcacy of lower
dosages or safety of short periods of higher dosage
treatment. In one preclinical study, Morgillo et al.36
showed that metformin sensitizes NSCLC cells to
November 2018 Metformin Efﬁcacy in KRAS/LKB1 Mutated NSCLC 1703geﬁtinib independently from EGFR and KRAS mutational
status, and recently published preliminary clinical data
have shown acceptable tolerability and promising anti-
cancer activity with the metformin-erlotinib combination
in EGFRWT NSCLCs, which are typically poorly respon-
sive to erlotinib monotherapy.37 The synergistic anti-
proliferative and pro-apoptotic effects of metformin and
geﬁtinib are limited to NSCLC cells with active LKB1,
whereas LKB1-mutated models do not beneﬁt from this
combination.36 Although these data seem to contradict
our ﬁndings of an exquisite sensitivity of LKB1-mutated
cells to the MC combination, they could be reconciled by
considering the different mechanism of action of geﬁti-
nib/erlotinib, which speciﬁcally inhibit EGFR, and
cisplatin, which induces DNA intra-strand and inter-
strand links that result in single- and double-strand
DNA breaks. The combination of metformin and geﬁti-
nib/erlotinib could inhibit two crucial signal trans-
duction pathways, namely the MAPK (via EGFR
inhibition by geﬁtinib/erlotinib) and mTOR (via
metformin-induced activation of AMPK, which requires
the presence of active LKB1) cascade, thus resulting in
synergistic antiproliferative and pro-apoptotic effects in
LKB1WT NSCLC. Conversely, metformin-induced meta-
bolic stress does not result in AMPK activation and
mTOR inhibition when LKB1 is inactive (LKB1MUT). If
KRAS mutations are contemporarily present, cells go on
proliferating even in conditions of metformin-induced
energetic and anabolic stress, which can expose them
to increased cisplatin-induced DNA damage and less
efﬁcient DNA repair, an energy- and anabolite-requiring
process.
In addition to the ongoing study on erlotinib-
metformin combination in EGFR WT NSCLC, metformin
is being tested in combination with ﬁrst-line, platinum-
based ChT in unselected NSCLC patient populations
(NCT 00637910). On the basis of our ﬁndings, as well as
of results from other groups, only speciﬁc NSCLC sub-
groups may beneﬁt from adding metformin to standard
ChT. We therefore expect that the ongoing studies could
fail to show any improvement from adding metformin to
cytotoxic ChT, and that careful patient selection on
biomarker expression will be essential to optimize clin-
ical results in future studies.
In conclusion, LKB1 mutations may deﬁne more
aggressive NSCLC subtypes even in the absence of other
common oncogene mutations, such as KRAS mutations.
However, the co-occurrence of LKB1/KRAS mutations
could deﬁne a speciﬁc subgroup of NSCLCs characterized
by exquisite sensitivity to the combination of metformin-
induced metabolic stress and cisplatin-induced replica-
tion stress and DNA damage. In particular, the MC
combination could speciﬁcally target the population of
CD133þ cells that are involved in the development ofsecondary resistance to cisplatin. Despite some limita-
tions of our study, including the relatively small number
of patients analyzed and the high metformin dosage
needed to produce meaningful biological effects in both
in vitro and in vivo experiments, targeting LKB1/KRAS
co-mutated tumors with the MC combination may
represent a novel therapeutic strategy for the treatment
of this aggressive subgroup of NSCLC. Based on excellent
safety proﬁle and low costs of metformin, we believe
that our results provide sufﬁcient evidence to encourage
the conduction of clinical trials to assess the antitumor
activity of cisplatin-pemetrexed-metformin triple ther-
apy as ﬁrst-line treatment of patients with LKB1/KRAS
co-mutated NSCLCs who are not candidate to receive
pembrolizumab.
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